Key clinical point: Niraparib improves time without symptoms and toxicity vs. placebo in recurrent ovarian cancer.
Major finding: Niraparib was associated with a mean TWiST benefit of 2.95 and 1.34 years vs. placebo.
Study details: A TWiST analysis of data from the phase 3 ENGOT-OV16/NOVA trial of 553 enrolled patients; 138 in the gBRCA cohort assigned to niraparib and 65 to placebo, and 234 patients in the non-gBRCA cohort assigned to niraparib and 116 to placebo.
Disclosures: Dr. Matulonis is a consultant for 2X Oncology, Merck, Mersana, Fujifilm, Immunogen, and Geneos.
Matulonis U et al. SGO 2019: Abstract 1.